Clinical Trials Logo
  1. Home
  2. Healthy Adult Subjects
  3. NCT04629131

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TNM002 in Healthy Adults

Healthy Adult Subjects Clinical Trial

Official title:
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Intramuscular Administration of a Single Dose of TNM002 in Healthy Subjects

Clinical Trial Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics properties of TNM002 following a single intramuscular dose in healthy adult subjects.

Clinical Trial Description

The study a randomized, double-blinded, placebo-controlled, dose-escalation phase I trial. A total of 32 healthy adult subjects will be enrolled into 4 cohorts sequentially. Each participant will receive a single IM dose of TNM002 or placebo according to the cohort in which they were enrolled. After injection (Day 1), participants remain in the study site for observation up to 5 days. Following completion of the safety assessments and sampling for PK/PD analyses on Day 4, participants will be discharged from the study site. On Day 8, 15, 29, 43, 64 and 85, participants will return for safety assessments. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04629131
Study type Interventional
Source Trinomab Biotech Co., Ltd.
Contact
Status Completed
Phase Phase 1
Start date November 25, 2020
Completion date August 13, 2021
View Details
See also
  Status Clinical Trial Phase
Completed NCT03267732 - A Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518) Phase 1
Completed NCT05040113 - A Study On Human Mass Balance And Biotransformation Phase 1
Completed NCT01433835 - Safety and Pharmacokinetics of Single Oral Doses of MBX-400 in Healthy Volunteers Phase 1
Completed NCT04029090 - A Study to Evaluate the Effect of MCI-186 at Therapeutic and Supra-Therapeutic Doses on the QT Interval(QT)/Corrected QT Interval(QTc) Interval in Healthy Subjects Phase 1
Completed NCT04586985 - Safety, Tolerability and Pharmacokinetics of FTX-6058 Phase 1
Completed NCT04481789 - Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Males (Drug Interaction Study and Preliminary Regimen-Finding Study) Phase 1
Completed NCT06107205 - Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects Phase 1
Completed NCT04203862 - A Study of NPC-22 in Healthy Adult Males Phase 1
Recruiting NCT05641181 - A Trial of CRB4101 in Healthy Subjects Phase 1
Not yet recruiting NCT06063291 - Single Ascending Oral Dose Phase 1 Study of ID11052 in Healthy Adult Subjects Phase 1
Completed NCT04521192 - Bioequivalence of Fluzoparib(SHR3162) Study on Healthy Chinese Adult Subjects Phase 1
Completed NCT04400123 - A Bioequivalence Study of Famitinib Malate on Healthy Chinese Volunteers Phase 1
Completed NCT04811469 - Safety, Tolerability and Pharmacokinetics of CBP-174 in Healthy Adults Phase 1
Completed NCT04291846 - A Food Effect Study of SHR1459 on Healthy Chinese Adult Subjects Phase 1
Completed NCT01364441 - Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects Phase 1
Completed NCT02691702 - Multiple Dose Study Of BIIB118 (PF-05251749) In Healthy Volunteers Phase 1
Recruiting NCT05334043 - Pharmacokinetics and Bioavailability of Curcumin UP 30 Capsules in Healthy Adult Subjects Phase 1
Completed NCT04493281 - Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects Phase 1
Completed NCT01376063 - Study to Investigate the Interaction Between FG-4592 and Rosiglitazone in Healthy Adult Subjects Phase 1
Completed NCT04481750 - Study of Oral Edaravone in Healthy Adult Males Phase 1